ophthalmologytimes9h
ACELYRIN announces phase 2b/3 trial of izokibep did not meet primary endpoint, ceases further additional internal investment
The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.
GlobalData on MSN5d
MSD’s trial of combination therapy for ovarian cancer meets primary endpoint
US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...
Hosted on MSN5d
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
Cure Today12d
Tiragolumab Plus Tecentriq Misses Survival Endpoint for Lung Cancer Subset
The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...
Acsh.org6d
Moderna's mRNA Norovirus Vaccine Trials: To Hurl or Not to Hurl. That's the Endpoint.
Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...
PharmaTimes4d
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint
Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of ...
Candel Therapeutics announces CAN-2409 achieved primary endpoint
Candel Therapeutics (CADL) announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized ...